Finally, our study demonstrated a strong therapeutic potential for the treatment of cardiac disease using the variants AAV2-THPTPAD and AAV2-NLPGSGD equipped with the anti-hypertrophic lncRNA H19. The administration of a 14-times lower vector dose compared with our previous study using AAV9-H19 vectors29 led to a significant improvement in cardiac function and rescue from the cardiac hypertrophy phenotype. This evidence concerns the gene H19 and cardiac hypertrophy.